deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT00819221

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors

Sponsor: AstraZeneca

Conditions Solid Tumors
Interventions AZD2281 liposomal doxorubicin
Updated 20 times since 2017 Last updated: Aug 25, 2022 Started: Jan 5, 2009 Primary completion: Nov 30, 2011 Completion: Dec 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Solid Tumors trials with similar outcome

Browse all Solid Tumors trials

Listed as NCT00819221, this PHASE1 trial focuses on Solid Tumors and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 20 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  5. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  9. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  11. Oct 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  12. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  13. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  14. Apr 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  15. Jan 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations